Subject(s)
Affective Symptoms/physiopathology , Apathy/physiology , Psychotic Disorders/physiopathology , Social Behavior , Adolescent , Adult , Anhedonia/physiology , Cross-Sectional Studies , Factor Analysis, Statistical , Female , Hong Kong , Humans , Male , Prospective Studies , Risk , Volition , Young AdultABSTRACT
OBJECTIVE: Epigallocatechin gallate (EGCG), the major chemical constituent of green tea, exhibits remarkable anti-tumor effect properties. In the present work, we aim to explore the effect and underlying mechanism of EGCG on multiple myeloma (MM) cells. MATERIALS AND METHODS: The effects of EGCG on MM cells proliferation and apoptosis were determined by CCK-8 assay and flow cytometry assay. The siRNAs were used to inhibit endogenous expression of EZH2. Enforced expression of EZH2 in U266 cells was accomplished by transfecting EZH2 plasmid. RESULTS: EGCG suppressed proliferation and induced apoptosis in U266 cells, which accompanied by EZH2 inhibition. Moreover, we revealed that enforced expression of EZH2 increased MM cells proliferation and reduced cell apoptosis, whereas EGCG partially reversed the effects of EZH2 on MM cells progression. In addition, qRT-PCR and Western blot showed that EZH2 overexpression increased Bcl-2 expression, and decreased BAX, BAK1 and cytochrome c expression in U266 cells exposed to EGCG. CONCLUSIONS: Our data showed that EGCG inhibited MM cells proliferation and induced apoptosis by targeting EZH2 and modulated mitochondrial apoptosis pathway, indicating EGCG might act as an adjuvant for chemotherapy of MM patients.
Subject(s)
Apoptosis/drug effects , Catechin/analogs & derivatives , Cell Proliferation/drug effects , Enhancer of Zeste Homolog 2 Protein/antagonists & inhibitors , Enhancer of Zeste Homolog 2 Protein/metabolism , Multiple Myeloma/metabolism , Apoptosis/physiology , Catechin/chemistry , Catechin/pharmacology , Cell Line, Tumor , Cell Proliferation/physiology , Humans , Mitochondria/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , TeaABSTRACT
Recent evidence from a comprehensive genome analysis and functional studies have revealed that FOXM1 is a crucial metastatic regulator that drives cancer progression. However, the regulatory mechanism by which FOXM1 exerts its metastatic functions in cancer cells remains obscure. Here, we report that DLX1 acts as a FOXM1 downstream target, exerting pro-metastatic function in ovarian cancers. Both FOXM1 isoforms (FOXM1B or FOXM1C) could transcriptionally upregulate DLX1 through two conserved binding sites, located at +61 to +69bp downstream (TFBS1) and -675 to -667bp upstream (TFBS2) of the DLX1 promoter, respectively. This regulation was further accentuated by the significant correlation between the nuclear expression of FOXM1 and DLX1 in high-grade serous ovarian cancers. Functionally, the ectopic expression of DLX1 promoted ovarian cancer cell growth, cell migration/invasion and intraperitoneal dissemination of ovarian cancer in mice, whereas small interfering RNA-mediated DLX1 knockdown in FOXM1-overexpressing ovarian cancer cells abrogated these oncogenic capacities. In contrast, depletion of FOXM1 by shRNAi only partially attenuated tumor growth and exerted almost no effect on cell migration/invasion and the intraperitoneal dissemination of DLX1-overexpressing ovarian cancer cells. Furthermore, the mechanistic studies showed that DLX1 positively modulates transforming growth factor-ß (TGF-ß) signaling by upregulating PAI-1 and JUNB through direct interaction with SMAD4 in the nucleus upon TGF-ß1 induction. Taken together, these data strongly suggest that DLX1 has a pivotal role in FOXM1 signaling to promote cancer aggressiveness through intensifying TGF-ß/SMAD4 signaling in high-grade serous ovarian cancer cells.
Subject(s)
Forkhead Box Protein M1/metabolism , Homeodomain Proteins/genetics , Ovarian Neoplasms/genetics , Ovarian Neoplasms/metabolism , Signal Transduction , Smad4 Protein/metabolism , Transcription Factors/genetics , Transforming Growth Factor beta/metabolism , Animals , Binding Sites , Cell Line, Tumor , Cell Movement/genetics , Disease Models, Animal , Disease Progression , Female , Heterografts , Humans , Mice , Neoplasm Grading , Neoplasm Metastasis , Nucleotide Motifs , Ovarian Neoplasms/pathology , Promoter Regions, Genetic , Protein Binding , Transcriptional ActivationABSTRACT
IMPORTANCE: The prognostic significance of competing constructs and operationalizations for brief psychotic episodes (acute and transient psychotic disorder [ATPD], brief psychotic disorder [BPD], brief intermittent psychotic symptoms [BIPS], and brief limited intermittent psychotic symptoms [BLIPS]) is unknown. OBJECTIVE: To provide a meta-analytical prognosis of the risk of psychotic recurrence in patients with remitted first-episode ATPD, BPD, BIPS, and BLIPS and in a benchmark group of patients with remitted first-episode schizophrenia (FES). We hypothesized a differential risk: FES > ATPD > BPD > BIPS > BLIPS. DATA SOURCES: The Web of Knowledge and Scopus databases were searched up to May 18, 2015; the articles identified were reviewed as well as citations of previous publications and results of a manual search of the reference lists of retrieved articles. STUDY SELECTION: We included original articles that reported the risk of psychotic recurrence at follow-up for patients in remission from first-episode ATPD, BPD, BLIPS, BIPS, and FES. DATA EXTRACTION AND SYNTHESIS: Independent extraction by multiple observers. Random-effects meta-analysis was performed, and moderators were tested with meta-regression analyses, Bonferroni corrected. Heterogeneity was assessed with the I2 index. Sensitivity analyses tested the robustness of the results. Publication bias was assessed with funnel plots and the Egger test. MAIN OUTCOMES AND MEASURES: Proportion of patients with baseline ATPD, BPD, BLIPS, and BIPS who had any psychotic recurrence at 6, 12, 24, and 36 or more months of follow-up. RESULTS: Eighty-two independent studies comprising up to 11,133 patients were included. There was no prognostic difference in risk of psychotic recurrence between ATPD, BPD, BLIPS, and BIPS at any follow-up (P > .03). In the long-term analysis, risk of psychotic recurrence (reported as mean [95% CI]) was significantly higher in the FES group (0.78 [0.58-0.93] at 24 months and 0.84 [0.70-0.94] at ≥ 36 months; P < .02 and P < .001, respectively) compared with the other 4 groups (0.39 [0.32-0.47] at 24 months and 0.51 [0.41-0.61] at ≥ 36 months). There were no publication biases. Sex and exposure to antipsychotic medication modulated the meta-analytical estimates (.002 < P < .03). CONCLUSIONS AND RELEVANCE: There are no prognostic differences in risk of psychotic recurrence between ATPD, BPD, BLIPS, and BIPS constructs of brief psychotic episodes. Conversely, there is consistent meta-analytical evidence for better long-term prognosis of brief psychotic episodes compared with remitted first-episode schizophrenia. These findings should influence the diagnostic practice and clinical services in the management of early psychosis.
Subject(s)
Psychotic Disorders/diagnosis , Psychotic Disorders/psychology , Schizophrenia/diagnosis , Schizophrenic Psychology , Acute Disease , Adult , Diagnosis, Differential , Female , Humans , Male , Predictive Value of Tests , Prognosis , Psychotic Disorders/drug therapy , Recurrence , Schizophrenia/drug therapyABSTRACT
An informal demonstration is offered, which strongly supports previous contentions that, when the elements of a Poggendorff display appear to be arranged in pictorial space such that the two critical line segments are at different heights, an illusory impression of misalignment may occur. A second pair of demonstrations shows, however, that such a height difference is neither a necessary nor a sufficient cause of the illusion. In addition, the harmful effect of adding certain pictorial elements to the standard Poggendorff pattern requires a new understanding.
